X

Trial Profile

A Single-center, Open Label, Single-dose Study to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics of ACT-132577

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aprocitentan (Primary)
Indications Cardiovascular disorders; Hypertension
Focus Pharmacokinetics
Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

Most Recent Events

12 Aug 2019 Results assessing the effect of several renal function impairment on the pharmacokinetics of aprocitentan published in the Clinical Drug Investigation
08 Nov 2017 Status changed from recruiting to completed.
26 Oct 2017 Planned End Date changed from 29 Sep 2017 to 30 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com